📰 Promising Efficacy News
Promising Efficacy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Promising Efficacy. Real-time updates on events, politics, business and more.
December 21, 2023
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient...
November 16, 2023
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with
October 30, 2023
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL...
June 26, 2023
Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to
December 11, 2021
Investegate announcements from F. Hoffmann-La Roche Ltd, Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab
January 3, 2021
Following is a transcript of their remarks: Susan OBrien, MD: Hi, everyone, and welcome to this roundtable where were going to discuss CLL presentations at ASH 2020 this year. Im Dr. Susan OBrien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and Im joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering. We have two presentations today on the TRANSCEND clinical trial, and that is an i...